Tyrosine Kinases And Its Receptors: Emphasis On Activation Signaling Pathways And Inhibitors.

The most primary concept in multicellular organisms is the binding of ligands and receptors to perform a particular catalytic activity. Tyrosine kinases are activated by ligand-receptor binding which leads to autophosphorylation of tyrosine. They are further divided into receptor tyrosine kinases and non-receptor tyrosine kinases, which are interrelated to each other. These receptors and their proteins are involved in maintaining the structural integrity of the cell, and further activates cell proliferation, survival, migration as well as apoptosis. Hence, it involves cancer metastasis and acts as a target for its inhibition. As we know, the formation of cancer is due to genetic mutations, and these receptors play the role of a harbinger of cancer. Therefore, targeting these proteins and their receptors directly affects the origin which becomes the cause for the treatment. Furthermore, there are various tyrosine kinase inhibitors developed and approved by the FDA, which directly or indirectly interfere with the signaling pathways, inhibiting metastasis. In addition, recent advances have been made, such as targeting the RET gene, development of Bruton’s tyrosine kinase inhibitors, discovery of combination therapies involving platinum-based chemotherapy with EGFR-TKIs, which also enhances long-term survival, etc.